首页 | 官方网站   微博 | 高级检索  
     

晚期非小细胞肺癌3种化疗方案的成本-效果分析
引用本文:陈彦清. 晚期非小细胞肺癌3种化疗方案的成本-效果分析[J]. 中国药业, 2007, 16(7): 29-30
作者姓名:陈彦清
作者单位:四川省攀枝花市中心医院药房,四川,攀枝花,617000
摘    要:目的探讨晚期非小细胞肺癌(NSCLC)不同化疗方案的临床疗效和经济学效果。方法将178例晚期NSCLC患者随机分为EP组(依托泊苷注射液+注射用顺铂)、NP组(酒石酸长春瑞宾注射液+注射用顺铂)、GP组(盐酸吉西他滨注射液+注射用顺铂)3组,运用药物经济学成本-效果分析方法,对3种化疗方案进行分析和评价。结果EP,NP,GP方案的有效率分别为38.9%,46.5%,56.6%,一个疗程的化疗费用分别为11930.60元、42684.25元、44195.87元。在EP方案的基础上,每增加一个单位效果,NP方案、GP方案所需追加的成本分别为4046.53元、1822.90元。结论GP方案为晚期NSCLC的较好治疗方案。

关 键 词:非小细胞肺癌  化疗方案  成本-效果分析  药物经济学
文章编号:1006-4931(2007)07-0029-02
修稿时间:2006-09-07

Cost- effectiveness Analysis of Three Chemotherapy Schemes for Treatment of Advanced Non- small Cell Lung Cancer
Chen Yanqing. Cost- effectiveness Analysis of Three Chemotherapy Schemes for Treatment of Advanced Non- small Cell Lung Cancer[J]. China Pharmaceuticals, 2007, 16(7): 29-30
Authors:Chen Yanqing
Affiliation:Department of Pharmacy, Central Hospital of Panzhihua City, Sichuan Province, Panzhihua, Sichuan, China 617000
Abstract:Objective To investigate the economic effects of three chemotherapy schemes in the treatment of non- small cell lung cancer (NSCLC).Methods 178 cases of advanced NSCLC were randomly divided into 3 groups,group EP,group NP and group GP.The cost effectiveness of the 3 groups were compared using pharmaceutical economics.Results 3 schemes costed 11 930.60 yuan,42 684.25 yuan and 44 195.87 yuan respectively.The effective rates were 38.9% ,46.5% and 56.6% respectively.On the basis of scheme EP,scheme NP and GP increased the cost of 4 046.53 yuan and 1 822.90 yuan respectively.Conclusion Scheme GP is the preferable choice.
Keywords:non- small cell lung cancer   chemotherapy scheme   cost- effectiveness analysis   pharmaceutical economics
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号